Best-practice recommendations for treatment of patients infected with human immunodeficiency virus (HIV) are continually evolving and now include strategies related to early initiation of antiretroviral therapy (ART) in patients with newly diagnosed HIV.1 Rapid, same-day ART initiation protocols offer a promising option for improving linkage to HIV care, decreasing time to viral suppression, and improving long-term viral suppression.2 Shorter time to viral suppression is associated with improved short- and long-term outcomes for people living with HIV, and benefits the community by decreasing the period in which individuals have transmittable virus.3 Implementation of same-day ART requires a sustained emphasis on the importance of viral suppression for HIV prevention, as well as technical and logistical assistance for its implementation.4 Further, rapid-ART protocols and services must be accompanied by innovative strategies to promote retention in care, especially within vulnerable populations.5 Geared to the needs of HIV-specialist clinicians, this HIV Experts and Evidence™ live meeting series will present recent data related to rapid ART initiation, solutions to logistical and clinical barriers that can impede access to same-day ART regimens, and real-world approaches to enhanced retention in care.
- U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1ćInfected Adults and Adolescents Living with HIV. Last reviewed and updated October 25, 2018. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Accessed February 11, 2019.
- Pilcher CD, et al. The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
- The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
- Colasanti J, et al. Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States. Open Forum Infect Dis. 2018;5(6):ofy104
- Coffey S, et al. RAPID ART: High virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2018 [Epub ahead of print].
Getting to Zero: Ending the HIV Epidemic
Early, Sustained Viral Suppression A - Key Disease-Management and Prevention Strategy
Rapid Antiretroviral Therapy (ART) Initiation: Operationalizing Early Viral Suppression
Addressing Barriers to Rapid Start
Manage This Patient: An Interactive Case-Based Activity
Concluding Comments: Looking Forward— Will You Have a Rapid ART Initiation Protocol in Place in 1 Year?
This activity is intended for infectious diseases and HIV– specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
After completing this activity, the participant should be better able to:
- Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
- Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
- Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates each activity in this live series for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-19-053-L02-P).
This is a knowledge-based activity.
Instructions to Receive Credit
To receive credit for this activity, submit a completed activity posttest and evaluation form at the conclusion of the program. You will be emailed a certificate within 3 weeks. If you do not receive your credit at that time, please contact email@example.com. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Christa Master prior to the live event at firstname.lastname@example.org.
There is no fee for this educational activity
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.